

Award Number: W81XWH-11-1-0743

TITLE: Regenerative Medicine for Battlefield Injuries

PRINCIPAL INVESTIGATOR: David L. Stocum

CONTRACTING ORGANIZATION: Indiana University  
Indianapolis, IN 46202

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |             |                          |                            | Form Approved<br>OMB No. 0704-0188                       |                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------|----------------------------|----------------------------------------------------------|-------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |             |                          |                            |                                                          |                                           |
| 1. REPORT DATE<br>October 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |             | 2. REPORT TYPE<br>Annual |                            | 3. DATES COVERED<br>19 September 2012 -18 September 2013 |                                           |
| 4. TITLE AND SUBTITLE<br><br>Regenerative Medicine for Battlefield Injuries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |                          |                            | 5a. CONTRACT NUMBER                                      |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          |                            | 5b. GRANT NUMBER<br>W81XWH-11-1-0743                     |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          |                            | 5c. PROGRAM ELEMENT NUMBER                               |                                           |
| 6. AUTHOR(S)<br><br>David L. Stocum<br><br>E-Mail: dstocum@iupui.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |                          |                            | 5d. PROJECT NUMBER                                       |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          |                            | 5e. TASK NUMBER                                          |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          |                            | 5f. WORK UNIT NUMBER                                     |                                           |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>Indiana University<br>Indianapolis, IN 46202                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |             |                          |                            | 8. PERFORMING ORGANIZATION REPORT NUMBER                 |                                           |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |             |                          |                            | 10. SPONSOR/MONITOR'S ACRONYM(S)                         |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          |                            | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)                   |                                           |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            |                                                          |                                           |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |             |                          |                            |                                                          |                                           |
| 14. ABSTRACT The purpose of this research is to identify the optimum combination of growth factors that stimulate cartilage regeneration across a critical size defect (CSD) in the fibula, using the axolotl, <i>Abystoma mexicanum</i> as a model system. The scope of the research is to characterize combinations of soluble factors (growth factors and tissue extracts) absorbed into a standard scaffold of pig small intestine submucosa (SIS). From October 2011 to April 2012, we determined the CSD as slightly less than 40% the length of the fibula.fracture, characterized the response to fracture and defects of various sizes, and identified 7 growth factors involved in fracture repair by bioinformatic analysis. We determined that regeneration takes place over gaps of up to 20%, but not at 40 and 50% and that SIS scaffold alone does not promote regeneration. In April 2013 we presented a poster summarizing this data at the Experimental Biology meeting in Boston. Since then, we have been testing the ability of a number of growth factor combinations, blastema extract, and limb tissue extract to promote cartilage regeneration across 50% gaps (20% greater than the actual CSD). Three sets of factors promoted such regeneration by 3 months post-implant, the growth factor combinations BMP4/VEGF and BMP4/HGF, and protein extract of intact limb tissue, of which the latter two gave the best results. We determined that the best way to image the regenerating tissue was by whole mount methylene blue staining and routine H&E histology, reserving micro-CT imaging for bone only. We think BMP4/HGF and tissue extract were successful because they initiated the whole cascade of events required for cartilage development. These results indicate that the axolotl fibula can be used as an in vivo screening system for soluble factors (as well as scaffolds) that promote cartilage regeneration across a CSD. |             |                          |                            |                                                          |                                           |
| 15. SUBJECT TERMS<br>Regeneration across a critical size defect in axolotl fibula, efficacy of growth factor combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |             |                          |                            |                                                          |                                           |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |                          | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES                                      | 19a. NAME OF RESPONSIBLE PERSON           |
| a. REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | b. ABSTRACT | c. THIS PAGE             |                            |                                                          | USAMRMC                                   |
| U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | U           | U                        | UU                         | 13                                                       | 19b. TELEPHONE NUMBER (include area code) |

## Table of Contents

|                                                         |          |
|---------------------------------------------------------|----------|
| Cover Page.....                                         | 1        |
| Report Documentation Page.....                          | 2        |
| Table of Contents.....                                  | 3        |
| Introduction.....                                       | 4        |
| Body.....                                               | 4        |
| <i>1. Results of Implanting SIS scaffold Alone.....</i> | <i>4</i> |
| <i>2. Selection of Growth Factor Combinations.....</i>  | <i>4</i> |
| <i>3. Testing Growth Factor Combinations.....</i>       | <i>4</i> |
| <i>4. Results of Growth Factor Treatments.....</i>      | <i>5</i> |
| Key Research Accomplishments.....                       | 6        |
| Reportable Outcomes.....                                | 7        |
| Conclusion.....                                         | 8        |
| References.....                                         | 8        |
| Appendix.....                                           | 8        |
| Supporting Data.....                                    | 8        |

## Introduction

The subject of our research is development of the urodele salamander *Ambystoma mexicanum* as a model to find the optimum set of growth factors to enable regeneration of a cartilage template across a critical size defect (CSD) in the long bones of the extremities. Unlike most models that attempt to regenerate bone directly, with less than optimum filling, regeneration of a cartilage template mimics the initial step of both the normal development of a long bone and fracture repair. The axolotl can be used to screen single molecules or combinations of molecules for their ability to stimulate regeneration across a CSD. This model has advantages over mammalian CSD models in that there is greater ease of surgical operation and tissue processing, no requirement for bone fixation, and is less expensive to maintain<sup>1</sup>. Our purpose is to identify the optimum combination of growth factors that simulate cartilage regeneration across a CSD (and ultimately, the optimum scaffold to deliver these factors). The scope of our research includes defining the CSD for a long bone of the lower leg, the anatomical and histological characterization of cartilage and bone regeneration over defects less than, and equal to or greater than, the CSD, defining protein release characteristics from a standard SIS delivery scaffold, identifying the optimum growth factor combination to be delivered through biochemical analysis of axolotl limb and regeneration blastema protein extracts and by bioinformatic techniques, and testing/verifying the effectiveness of this combination by delivery in the appropriate scaffold.

## Body

### *1. Results of Implanting SIS scaffold Alone*

We confirmed that no intrinsic regeneration takes place in a 50% CSD of the fibula, and that the SIS scaffold used as a growth factor delivery vehicle did not promote regeneration across a 50% CSD.

### *2. Selection of Growth Factor Combinations*

During the first quarter, we identified, by bioinformatics mining<sup>2</sup> of the literature on fracture repair, eight growth factors to test in four combinations for their ability to promote regeneration across a 50% CSD. The growth factors were: VEGF-A, HGF, FGF-2, TGF $\beta$ -3, BMP4, PDGF-A, EGF, and PDGF-B. All of the commercial growth factors available, except EGF, had an amino acid sequence homology to the corresponding *Xenopus* growth factors (the closest amphibian to the axolotl for which such data were available) of 64% or greater. EGF was eliminated from the experiments because of its low homology (41%), as was PDGF-B (homology = 39%). Six combinations of the remaining six growth factors, along with limb blastema protein extract and intact limb tissue extract, were tested for their ability to promote regeneration across a 50% CSD. We used a physical maceration and cell lysis procedure to extract a high concentration of protein (5.76 mg/ml) from blastema and tissue cells. These extracts induced no inflammatory reaction when injected into the muscle of the tibia-fibula.

### *3. Testing Growth Factor Combinations*

During the second quarter, we focused on setting up the experiments to test growth factor combinations and protein extracts on CS defects of 50%. Lengths of scaffold equaling the size of the defect were soaked in 50  $\mu$ l solutions of the growth factor combinations overnight at 4°C. Stock solutions of the growth factor combinations were made by centrifuging the growth factors at 13,000 rpm and re-suspending the pellet in amphibian PBS to obtain concentrated solutions. Then aliquots of individual growth factors were combined to obtain 200  $\mu$ l of each combination at the concentrations shown in Table 1. Growth factor concentrations were decided by reference to the published literature on the use of each factor for in various biological systems, including wound repair and bone regeneration. To absorb the growth factor combinations into the scaffolds, lengths of scaffold equivalent to half the length of the fibula were cut, and five scaffolds at a time were immersed in 50 $\mu$ l of growth factor solution contained in a small plastic well made from the inverted cap of an Eppendorf tube. The scaffolds were allowed to absorb the growth factor solution overnight at 4°C and then

were implanted into 50% segment defects made in the fibula, under 0.08% MS-222 anesthesia. Incisions were closed with silk suture and the animals kept in analgesic-strength (0.02%) MS-222 overnight before returning to maintenance water the next day. In addition, we injected (under anesthesia) the polychrome dyes calcein (15µg/gm body wt), alizarin complexone (30µg/gm body wt), and calcein blue (30 µg/gm body wt) into the operated limbs to enable visualization of any osteogenesis.

Eight groups of implants were made to 50% segment defects in the fibulas of axolotls that averaged 14 cm in snout-tail tip length (**Table 1**). Six of the groups were different growth factor combinations, and two were protein extracts of mid-late bud regeneration blastemas, and intact limb tissues, respectively.

**Table 1**

| <u>Treatment Group</u>         | <u>GF Concentration</u> | <u># of animals</u> |
|--------------------------------|-------------------------|---------------------|
| 1 <sup>a</sup> . Amphibian PBS | ---                     | 10                  |
| 2 <sup>b</sup> . BMP-4         | 10 ng/µl                | 10                  |
| VEGF                           | 25 ng/µl                |                     |
| 3. BMP-4                       | 10 ng/µl                | 10                  |
| HGF                            | 10 ng/µl                |                     |
| 4. BMP-4                       | 10 ng/µl                | 10                  |
| VEGF                           | 25 ng/µl                |                     |
| HGF                            | 10 ng/µl                |                     |
| 5. BMP-4                       | 10 ng/µl                | 10                  |
| VEGF                           | 25 ng/µl                |                     |
| HGF                            | 10 ng/µl                |                     |
| FGF-2                          | 8 ng/µl                 |                     |
| 6. BMP-4                       | 10 ng/µl                | 10                  |
| VEGF                           | 25 ng/µl                |                     |
| HGF                            | 25 ng/µl                |                     |
| FGF-2                          | 8 ng/µl                 |                     |
| EGF                            | 10 ng/µl                |                     |
| TGFβ-3                         | 2ng/µl                  |                     |
| PDGF-AA                        | 10 ng/µl                |                     |
| 7. Blastema protein extract    | 7µg/µl                  | 10                  |
| 8. Limb protein extract        | 6µg/µl                  | 10                  |

<sup>a</sup>Negative control

<sup>b</sup>Positive control from Reference 15.

#### **4. Results of Growth Factor Treatments**

During Quarter 3, we harvested implanted limbs that had been regenerating for two months with 10% and 20% gaps. These limbs had been injected with three fluorochrome dyes for live imaging to detect bone regeneration. Small amounts of bone regeneration were detected at the proximal and distal ends of 50% gaps treated by scaffold implant with VEGF/BMP4 (Figs 1, 2).

During Quarter 4, we have sectioned three-month samples of 50% defects and stained the sections with H&E to assess regeneration. We detected regeneration in three sets of samples: BMP4/VEGF-treated, BMP4/HGF-treated, and the limb tissue extract-treated samples (Figs 3-8). Of the three groups, the combination BMP4/HGF resulted in the most substantive regeneration, nearly the whole length of the gap. Interestingly, regeneration appears to be polarized, extending from the proximal stump of the fibula. These findings allow us to now focus on these three treatment groups. Going forward, we will examine 4 and 5-month samples by methylene blue stain for whole mounts and trichrome staining of sections. We will also set up a new group of implants treated with the successful factor combinations factors.

We will also be changing our scaffold strategy, and reducing the size of the gap to approach the actual CSD size. Our defect size of 50% is ~20% greater than the actual critical size defect of slightly less than 40% that we established earlier. We feel that the 40% gap is a more realistic challenge for the system, since we have found that in some cases, the bone stumps dissolve on one or both ends. Because the regeneration is polarized, it may be that an intact bone stump is necessary for the initiation of regeneration. Another problem is that in either a 40% or 50% size gap, the distal end of the fibula often becomes deflected at an angle to the proximal end. The braided SIS scaffold we have been using is not stiff enough to keep the ends of the fibula aligned; it unravels when hydrated by body fluids. We have obtained a rod form of SIS that we think will maintain better alignment and will re-test a polycaprolactone scaffold synthesized by Dr. Bottino. In previous tests of this scaffold, freshly synthesized scaffold was rejected from the limb, probably because of an inflammatory reaction to some of the solvents used in the synthetic process. This scaffold will be re-tested after washing with several changes of PBS over two days.

### **Key Research Accomplishments**

- Determined that long-term implants of SIS scaffold alone do not promote regeneration across a 50% gap in the axolotl fibula
- Determined that the growth factor combination of bone morphogenetic protein 4 and hepatocyte growth factor, and protein extract from intact limb tissue both promote regeneration within a 50% defect.
- Revealed shortcomings of braid SIS, leading to better delivery system of rod SIS scaffold and tubular polycaprolactone scaffold.

## Reportable Outcomes

### Poster and Abstract: Experimental Biology, April 22, 2013, Boston MA

Program No. 751.4

#### Abstract

We determined the critical size defect (CSD) for regeneration of the axolotl fibula by surgically removing bone segments comprising 10, 20, 40, and 50% of the length of the fibula in 15-20 cm axolotls. The limbs were first subjected to X-ray and Micro-CT imaging. Half the specimens were stained with methylene blue/alizarin red for cartilage/bone and the other half sectioned and stained with H&E. H&E staining revealed the initiation of cartilage formation in 10% and 20% defects by one month; cartilage and bone were regenerated by three months. None of the 40% defects regenerated cartilage by two months post-operation, and 7/8 (87.5%) specimens failed to regenerate cartilage at three months. None of the 50% defects had regenerated cartilage after three months. H&E staining showed that the 40% and 50% defects filled in with fibrous soft tissue. We concluded that the CSD is slightly less than 40% of the length of the fibula. A pig small intestine submucosa (SIS) scaffold did not promote regeneration across a 50% defect. The scaffold degraded by two months after implantation while the defect was filled by connective tissue and disorganized muscle fibers. Our aim is to use the axolotl fibula as a new, easy to use model to screen for the optimum combination of growth factors/scaffold that promotes cartilage formation in a CSD, thus mimicking the first step of normal endochondral bone development and fracture repair.

## Characterization of Segment Defect Regeneration in the Axolotl Fibula

Xiaoping Chen, David L. Stocum

Department of Biology and Center for Regenerative Biology and Medicine, Indiana University-Purdue University Indianapolis, Indianapolis IN 46202



#### INTRODUCTION

The subject of our research is development of the urodele salamander *Ambystoma mexicanum* (axolotl) as a model to find the optimum set of growth factors that will enable regeneration of a cartilage template across a CSD in the long bones of the extremities. The regeneration of a cartilage template mimics the initial step of both the normal development of a long bone and fracture repair. The axolotl model can be used to screen single molecules or combinations of molecules for their ability to stimulate regeneration across a CSD.



#### METHODS

1. Bone segments comprising 10, 20, 40, and 50% of the length of the fibula were surgically removed in 15-20 cm axolotls (10 specimens/each group).
2. Fractured fibulae and fibulae with segment defects were analyzed over a three-month period.
3. The limbs were fixed and first subjected to X-ray and micro-computed tomography (Micro-CT) imaging.
4. Half the specimens (5/each group) were then stained with methylene blue/alizarin red for cartilage/bone and the other half sectioned and stained with H&E.
5. A standard braided pig small intestine submucosa (SIS) coated with gelatin was implanted into 50% defects to test for degradation after two months.

#### RESULTS

1. H&E staining of sections revealed the initiation of cartilage formation in 10% and 20% defects by one month. These defects went on to regenerate cartilage and bone by three months.
2. The X-ray, Micro-CT and methylene blue/alizarin red data showed that none of the specimens with 40% defects regenerated cartilage by two months post-operation, and that 7/8 (87.5%) specimens at three months post-operation failed to regenerate cartilage. None of the 50% defects had regenerated cartilage after three months. H&E stained sections showed that the 40% and 50% defects were filled in with fibrous soft tissue.
3. H&E staining and trichrome staining showed that the SIS degraded by two months after implantation while the defect was filled by connective tissue and disorganized muscle fibers.

#### Table 1. 10%-50% segment defect regeneration assay

| Assay 2 or 3 months post-operation | 10% Segment Defect | 20% Segment Defect | 40% Segment Defect | 50% Segment Defect |
|------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Histology(H&E stain)               | 4/5                | 4/4                | 0/4                | 0/5                |
| MBAR stain                         | 4/5                | 3/4                | 1/4                | 0/5                |
| Micro-CT                           | 4/5                | 2/4                | 1/4                | 0/5                |
| X-ray                              | 8/10               | 4/8                | 1/8                | 0/10               |

\*All specimens were first imaged by X-ray. Half the specimens were then subjected to Micro-CT and then MBAR staining. The remaining half of the specimens was sectioned for H & E staining. 10%-20% segment defect groups were assayed in 2 months post operation because more than half showed signs of regeneration on X-ray images. 40-50% segment defect groups were assayed in 3 months post operation.

#### RESULTS

Table 1 shows that chondrogenesis can be detected in H & E-stained 10µm sections earlier than methylene blue-stained whole mounts that detect the aggrecan proteoglycan in cartilage matrix. However, it takes two-three months for the cartilage to mature to the point where it can be easily visualized by Micro-CT or X-ray. The X-ray shows clearly that none(0/10) of the specimens with 50% segment defects regenerated across the gap and that 7/8 (87.5%) specimens of 40% segment failed to regenerate cartilage at three months post-operation. Longitudinal sections stained with H & E showed that the defect is filled in with fibrous soft tissue. None of the 50% defects had regenerated skeletal tissue even after three months.

#### Figure 1. 10% & 20% segment defect regeneration(2 months)




Figure 1A: Top, X-ray images of hind limbs in which a 10% segment defect was created in the mid fibula. Red arrows indicate cartilage formation in the defect space at two months post surgery (red arrow). Bottom: X-ray images of a 20% segment defect, showed cartilage formation in the defect space.

Figure 1B: Left, Micro-CT image of regeneration region (arrow) at two months. Middle, specimen stained with methylene blue for cartilage only and combined with alizarin red for bone (right).

Figure 1C: 20% segment defect specimen one month post-operation. H&E stained longitudinal section. The red lines indicate the region where cartilage bridges the gap. T = tibia.

#### Figure 2. 40% & 50% segment defect(3 months)




Figure 2A: Top, X-ray photos of eight 40% defect specimens. One specimen has bridged the segment defect gap with cartilage (arrow). Bottom, X-ray images of a 50% segment defect, showed no regeneration in the defect space.

Figure 2B: Left to right: Representative specimen imaged in succession by Micro-CT, methylene blue, and alizarin red. The cut ends of the fibula are capped and no cartilage has bridged the gap.

Figure 2C: Longitudinal sections of two specimens (40% defect and 50% defect). The segment defect in the fibula (SD) has filled in with fibrous connective tissue. T = tibia. F=fibula.

#### RESULTS

#### Figure 3. Gelatin-coated SIS inserted into a 50% defect in the fibula



Figure 3A: Gelatin-coated SIS inserted into a 50% defect in the fibula. The black strand is the suture that will be used to close the wound.

Figure 3B: X-ray images of 50% defect three months post-operation. No regeneration has occurred across the gap. T = tibia.

Figure 3B-C: 50% defect at one(top) and two months(bottom) after embedding a gelatin-coated SIS scaffold. No cartilage has regenerated. In the one-month specimen, the implanted scaffold is still visible within the gap (arrow). At two months, the scaffold is largely gone, and connective tissue and muscle has regenerated into the gap.

#### CONCLUSIONS

1. Cartilage formation was initiated in 10% and 20% defects by one month and these defects went on to regenerate cartilage and bone by three months.
2. None of the specimens with 40% defects regenerated cartilage by two months post-operation, and 7/8 (87.5%) of the specimens at three months post-operation failed to regenerate cartilage. None of the 50% defects regenerated cartilage after three months. The 40% and 50% defects were filled in with fibrous soft tissue.
3. From this data, we conclude that the critical size defect is slightly less than 40% of the length of the fibula.
4. A standard braided pig small intestine submucosa (SIS) coated with gelatin did not promote regeneration across a 50% defect. The scaffold degraded by two months after implantation while the defect was filled by connective tissue and disorganized muscle fibers.
5. The axolotl fibula is a new, easy to use model to screen for the optimum combination of growth factors/scaffold that promotes cartilage formation in a CSD, thus mimicking the first step of normal endochondral bone development and fracture repair.

#### REFERENCE

1. Song F, Li B, Stocum DL. Amphibians as research models for regenerative medicine. *Organogenesis*. 2010 Jul-Sep 6(3): 141-50.
2. Feng L, Miller DJ, Xia C, Iyie HL, Redwood P, Cameron JA, Stocum DL, Fang H, Jasak I. *Xenopus laevis* as a novel model to study long bone critical-size defect repair by growth factor-mediated regeneration. *Tissue Eng Part A*. 2011 Mar;17(3-6):691-701.
3. Stocum D.L., *Regenerative Biology and Medicine*, 2nded., p. 368 (2012)

#### ACKNOWLEDGEMENT

Research supported by Telemedicine & Advanced Technology Research Center, US Army Medical Research and Materiel Command. Award # W81XWH-11-1-0743.

## Characterization of Segment Defect Regeneration in the Axolotl Fibula

**Xiaoping Chen, David L. Stocum:** Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN 46202

We determined the critical size defect (CSD) for regeneration of the axolotl fibula by surgically removing bone segments comprising 10, 20, 40, and 50% of the length of the fibula in 15-20 cm axolotls. The limbs were first subjected to X-ray and micro-CT imaging. Half the specimens were stained with methylene blue/alizarin red for cartilage/bone and the other half sectioned and stained with H&E. H&E staining revealed initiation of cartilage formation in 10% and 20% defects by one month; cartilage and bone were regenerated by three months. None of the 40% defects regenerated cartilage by two months post-operation, and 7/8 (87.5%) failed to regenerate cartilage at three months. None of the 50% defects regenerated cartilage after three months. H&E staining showed that the 40% and 50% defects filled in with fibrous soft tissue. We concluded that the CSD is slightly less than 40% of the length of the fibula. A pig small intestine submucosa (SIS) scaffold did not promote regeneration across a 50% defect. The scaffold degraded by two months after implantation while the defect was filled by connective tissue and disorganized muscle fibers. Our aim is to use the axolotl fibula as a new, convenient model to screen for the optimum combination of growth factors and scaffolds that promote cartilage formation in a CSD, thus initiating the cascade of events in normal endochondral bone development.

**Research supported by the Telemedicine & Advanced Technology Research Center, US Army Medical Research and Materiel Command, Award # W81XWH-11-1-0743**

## Conclusion

Both BMP-4/HGF and intact limb tissue protein extract promote cartilage regeneration across a greater than CSD in the axolotl fibula, whereas other more complex combinations of growth factors, as well as regeneration blastema extract fail to do so. BMP-4/HGF trigger the initial events of a cascade that leads to cartilage formation, most likely by recruitment of MSCs cells from the periosteum of the adjacent tibia or fibroblasts from muscle and dermis.

## References

1. Song F., et al., *Organogenesis* **6**, 141 (2010).
2. Palakal M., et al., *Proc IEEE Comput Soc Bioinform Conf* **1**, 97 (2002).

## Appendix

None

## Supporting Data

Powerpoint Figures 1-8. Figs. 3-8 are longitudinal sections stained with H&E and photographed at 2.5X.

### Legends for Figures

Fig. 1: PBS-treated (A) and 50% CSD sample (B) treated with VEGF/BMP4 and injected successively with calcein (green), alizarine (red) and calcein blue. Harvested at 2 months post-surgery and treatment. There was very little or no bone regeneration during the first two weeks in the PBS-treated animal (green, red and blue overlap). Bone regeneration occurred in the VEGF/BMP4 sample (separation of green, red and blue).

Fig. 2: Micro-CT image of 50% CSD treated with VEGF/BMP4 and harvested at three months post-surgery. Bone regeneration had taken place from the distal cut end of the fibula (to the left).

Fig. 3. 50% fibular defect treated with BMP4/VEGF/HGF/FGF2/PDGFAA/TGF beta-3, three months post-implant. A small amount of regenerated cartilage (RC) was present at the proximal end of the fibula (PF). The distal end of the fibula (PF) was severely angled with respect to the proximal end. A small amount of cartilage appears to have regenerated transversely on the distal fibula stump (asterisk). Lines indicate the boundaries of the gap, within which appear to be remnants of the SIS scaffold. The adjacent tibia is indicated by the long arrow.

Fig. 4. Regeneration of cartilage across a 50% defect (areas enclosed within the rectangles) three months after treatment with BMP4/HGF. The cartilage is irregular in shape and is surrounded by a thin periosteal bone shell (blue arrow). Black arrow runs the length of the adjacent tibia. Proximal end of the tibia to the left. Note the muscle mass (black star) attached to the distal end of the regenerating cartilage.

Fig. 5. 50% defect three months after treatment with BMP4/HGF. In this case, an irregular secondary length of cartilage (orange arrow) was induced along the axis of the tibia (Black arrow). Vertical lines indicate the boundaries of the gap in the fibula. The distal tibia has been resorbed except for a nodule of cartilage. PT = proximal tibia; PF = proximal fibula stump.


Fig. 6. Another example of a 50% defect three months after treatment with BMP4/HGF. Cartilage is regenerating (asterisk) from the proximal stump of the tibia (PF).

Fig. 7: 50% defect three months after treatment with intact limb tissue extract. Vertical lines indicate the boundaries of the defect. Regenerated cartilage (green star) formed under the skin off to the side of the gap. There appears to be ossification in the center and development of a marrow cavity.



Fig. 8: 50% defect three months after treatment with BMP4/VEGFB. An irregular tongue of cartilage (asterisk) is regenerating from the distal end of the fibula (DF). The gap (green star) is filled with remnants of the SIS scaffold.

Negative control and VEGF+BMP4 treatment of 50% CSD at 2 months post-surgery



50% CSD treated with VEGF/BMP4

